T antigen-presenting cells therapeutics - Juno/Seattle

Drug Profile

T antigen-presenting cells therapeutics - Juno/Seattle

Alternative Names: T-APCs - Juno Therapeutics

Latest Information Update: 26 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Juno Therapeutics
  • Developer Juno Therapeutics; Seattle Children's Hospital
  • Class Cancer vaccines; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute lymphoblastic leukaemia
  • Preclinical Solid tumours

Most Recent Events

  • 09 May 2017 Phase-I clinical trials in Acute lymphoblastic leukaemia (In infants, In children, In adolescents, In adults, Second-line therapy or greater) in USA (Infusion)
  • 09 May 2017 Preclinical trials in Solid tumours in USA (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top